Department of Pathophysiology, School of Medicine, University of Athens, Mikras Asias Str 75, Athens 115 27, Greece.
Autoimmun Rev. 2016 Jul;15(7):695-703. doi: 10.1016/j.autrev.2016.03.004. Epub 2016 Mar 9.
Primary Sjӧgren's syndrome (pSS) is a complex autoimmune disease with distinct clinical phenotypes and variable outcomes. The systemic form of the disease is characterized by immune complex mediated manifestations and is complicated by lymphoma as a result of a polyclonal B cell hyperactivity that is evolving into B cell malignancy. In the past decades, well-established clinical and serological markers have been described in the literature to identify high-risk patients and to predict lymphoma development. However, specific biologic treatments have proven ineffective to control the disease. Significant research effort has been made to reveal the major underlying biological events in this subgroup and identify biomarkers for early diagnosis, prognosis and response to treatment. In this review, we summarize the current data for the proposed histological, molecular and genetic biomarkers.
原发性干燥综合征(pSS)是一种复杂的自身免疫性疾病,具有不同的临床表型和可变的结局。该疾病的系统性形式表现为免疫复合物介导的表现,并因多克隆 B 细胞活性增加导致淋巴瘤复杂化,进而发展为 B 细胞恶性肿瘤。在过去的几十年中,文献中已经描述了一些成熟的临床和血清学标志物,用于识别高危患者和预测淋巴瘤的发展。然而,特定的生物治疗方法已被证明无效,无法控制该疾病。为了揭示这一亚组中的主要潜在生物学事件,并确定用于早期诊断、预后和治疗反应的生物标志物,已经进行了大量的研究。在这篇综述中,我们总结了目前提出的组织学、分子和遗传生物标志物的相关数据。